Peptides Similar to Selank

Peptides Related to Selank#

Several peptides share functional overlap with Selank in tissue repair and healing research. Below is a detailed comparison of their mechanisms, efficacy, and potential for combination use.

Thymosin Beta-4 (TB-500)#

We compared the research efficacy of Selank, Thymosin β4 (TB‑500), and GHK‑Cu, prioritizing human randomized/controlled data and noting the presence or absence of head‑to‑head trials. Where possible, we report clinical endpoints, sample sizes, and safety, and we indicate gaps in the evidence base.

Head‑to‑head evidence No head‑to‑head human clinical trials directly comparing Selank versus Thymosin β4/TB‑500 or versus GHK‑Cu were identified. Available data allow only indirect comparison across separate studies and indications (e.g., anxiety for Selank; ocular surface disease and chronic ulcers for Thymosin β4; cosmetic skin outcomes for GHK‑Cu).

Strongest human clinical evidence by peptide

• Thymosin β4 (TB‑500) • Dry eye/ocular surface disease: A Phase 2, randomized, double‑masked trial (n=72) of 0.1% Tβ4 ophthalmic solution (RGN‑259) versus vehicle in a controlled adverse environment evaluated corneal fluorescein staining and ocular discomfort as co‑primary endpoints; the program reports significant improvements in signs/symptoms versus vehicle (trial registry and linked publication) (NCT01387347, NCT01393132). A smaller randomized, masked comparative study in severe dry eye (n=9) further assessed safety and corneal staining, OSDI, and tear break‑up time (NCT01393132). • Chronic skin ulcers: Two Phase 2, randomized, double‑blind, placebo‑controlled studies (each n=72) in venous stasis ulcers and in pressure ulcers used daily topical Tβ4 gel (0.01–0.1%) up to 84 days, assessing safety and incidence of complete wound closure by day 84 as key outcomes (NCT00832091, NCT00382174). These establish RCT‑level evaluation in chronic wound populations, although detailed efficacy magnitudes are variably reported in registries. • Overall: Multiple Phase 2 randomized/controlled trials across ocular and cutaneous wound indications, generally with acceptable safety on topical/ophthalmic use; some programs were terminated/withdrawn for logistical reasons (e.g., recruitment) (NCT00598871).

• GHK‑Cu (copper tripeptide) • Topical cosmetic/dermatologic studies: Controlled human studies (typically 8–12 weeks) report improvements in skin density, thickness, laxity, wrinkle parameters, and biopsy‑level collagen/elastin and MMP/TIMP modulation. One facial study (≈71 participants) and an eye‑area study (≈41) showed superiority over vehicle and certain comparators; endpoints included instrumental skin measures and clinical grading. Reviews summarizing these trials also note up‑regulation of extracellular matrix and broad gene‑expression effects relevant to tissue repair. • Overall: Evidence consists of small to moderate-sized randomized/controlled cosmetic trials and mechanistic data; indications are dermatologic/cosmetic rather than systemic medical conditions.

• Selank • Anxiety disorders: Published human data are limited. A 20‑patient clinical study reported as a conference abstract in generalized anxiety disorder (intranasal Selank 2.7 mg/day) found 40% “rapid responders” with marked Hamilton Anxiety Rating Scale (HARS) score reduction by day 3, and the remainder improving by day 14; pharmaco‑EEG changes were noted in rapid responders. A peer‑reviewed Russian review summarizes small clinical studies in GAD and neurasthenia and states anxiolytic effects comparable to the benzodiazepine medazepam, with antiasthenic/psychostimulatory benefits and fewer typical benzodiazepine‑like adverse effects; however, detailed randomized, blinded trial data are not provided. Mechanistic work in rats shows intranasal Selank upregulates hippocampal BDNF mRNA/protein within hours, potentially mediating anxiolytic/nootropic effects. • Overall: Human evidence for Selank is substantially weaker than for Tβ4 and GHK‑Cu in their respective domains, relying on small uncontrolled/observational reports and a conference abstract rather than published randomized, blinded trials.

Comparative assessment of research efficacy

• Rigor and quantity of human evidence • Thymosin β4 (TB‑500): Highest level among the three, with multiple Phase 2 randomized, masked, placebo‑controlled trials in medical indications (ocular surface disease; chronic ulcers), prespecified clinical endpoints (corneal staining, ocular discomfort; wound closure), and multicenter designs (NCT01387347, NCT00832091, NCT00382174, NCT01393132). • GHK‑Cu: Moderate evidence based on small to moderate randomized or controlled human cosmetic studies demonstrating improvements in skin structure/function and histologic markers; robust preclinical/mechanistic support, but clinical use largely cosmetic. • Selank: Lowest human evidence strength—no identified randomized, blinded clinical trials with published outcomes; existing reports suggest anxiolytic activity, but the evidence consists of small cohorts and a conference abstract; mechanistic animal data support plausibility.

• Efficacy signals by indication (indirect comparison) • Anxiety (Selank): Rapid HARS reductions in a subset of patients by day 3 and broader improvements by two weeks suggest potential clinical benefit; absence of published randomized, controlled trials precludes precise effect sizing and comparative efficacy claims to standard anxiolytics. • Ocular surface disease (Tβ4): Randomized Phase 2 data indicate improvement in corneal staining and symptoms after ~4 weeks, supporting efficacy for dry eye/epithelial healing (NCT01387347, NCT01393132). • Chronic ulcers (Tβ4): Randomized Phase 2 designs prioritized complete wound closure by day 84; program structure supports evaluation of clinically meaningful endpoints, though publicly accessible registries provide limited quantitative effect estimates (NCT00832091, NCT00382174). • Skin aging/cosmetic repair (GHK‑Cu): Controlled trials show improved skin biophysical parameters and collagen metrics over 8–12 weeks versus vehicle/comparators.

Safety

• Tβ4 topical/ophthalmic formulations were generally well tolerated in Phase 2 trials with adverse event monitoring (NCT01387347, NCT00832091, NCT00382174, NCT01393132).
• GHK‑Cu topical use has a favorable cosmetic safety record in controlled studies and long‑term cosmetic use.
• Selank reports suggest fewer benzodiazepine‑like adverse effects; detailed, controlled safety datasets are limited.

Synthesis and conclusion

• No direct head‑to‑head clinical comparisons exist between Selank and Thymosin β4/TB‑500 or GHK‑Cu. Indirectly, Thymosin β4 has the most advanced human clinical program with multiple randomized, masked, placebo‑controlled Phase 2 trials in medical indications (ocular surface disease, chronic ulcers) supporting efficacy signals and acceptable safety. GHK‑Cu has several small randomized/controlled human cosmetic trials showing improvements in skin structure/function and histologic markers, backed by mechanistic data. Selank’s human evidence remains preliminary, consisting of small observational/cohort reports and a conference abstract indicating anxiolytic effects and rapid responders; mechanistic animal data (hippocampal BDNF upregulation) support plausibility but not clinical efficacy. On current evidence, research efficacy ranks Tβ4 > GHK‑Cu > Selank, with the caveat of distinct indications and endpoints limiting direct comparability.

Comparison summary table

Mechanism Comparison#

Selank: primary mechanisms, targets, and pathways

• Receptor/target level: Experimental work supports a GABAergic component. In rat brain, Selank altered expression of GABA system genes and showed transcriptional changes overlapping with exogenous GABA, consistent with allosteric modulation at GABAA receptors rather than direct agonism (time-matched changes and suppression of GABA-induced shifts when co-applied). Electrophysiology shows Selank increased the frequency of spike-dependent inhibitory postsynaptic currents in CA1, indicating enhanced inhibitory interneuron activity, consistent with GABAergic modulation.
• Peptidase/opioid axis: Selank inhibits enkephalin-degrading enzymes in serum, increasing endogenous enkephalins, a plausible contributor to anxiolysis.
• Downstream signaling and gene programs: Transcriptome studies report broad regulation of neurotransmission and immune genes, including transporters and ion homeostasis (e.g., NCX3 upregulation, linked to Akt/PKB-mediated neuroprotection). Selank also exerts immunomodulation and antiviral actions, shifting cytokine programs (IFN-α/IL-12 induction; IL-6 gene suppression). Reports also note BDNF upregulation following Selank administration, aligning with neurotrophic effects.

Semax (ACTH(4–7)PGP) and ACTH-like fragments: targets and pathways

• Binding/targeting: Radioligand studies demonstrate specific, high-affinity Semax binding sites in rat basal forebrain membranes, supporting a receptor-mediated mechanism; melanocortin receptors are suggested but not directly shown to mediate Semax binding in these preparations.
• Neurotrophin signaling: Robust induction of BDNF and NGF mRNAs in glia and BDNF protein increases in vivo after Semax, with upregulation of TrkB mRNA and increased TrkB tyrosine phosphorylation, implicating BDNF–TrkB signaling; broader pathway analyses implicate Wnt and NF-κB cascades.
• Neurotransmission and GABA/glycine modulation: Semax modulates GABA- and glycine-activated ionic currents and peptide–GABA ligand interactions in neuronal membranes, indicating overlap with Selank at the level of inhibitory neurotransmission.
• Ischemia transcriptomics: In rodent ischemia–reperfusion, Semax suppresses inflammatory gene clusters and activates neurotransmission-related genes; proteomic readouts include increased active CREB and reduced JNK/c-Fos/MMP-9, consistent with neuroprotective pathway engagement. ACTH(6–9)PGP shows highly overlapping transcriptomic compensation with Semax at 24 h post-tMCAO and prosurvival pathway activation in cells (NRF2/NF-κB), indicating shared mechanisms within the ACTH-fragment class.

Tuftsin: receptor and signaling axis

• Receptor: Tuftsin directly binds Neuropilin‑1 (NRP1), competing with VEGF for NRP1 binding and modulating VEGF/VEGFR2 signaling via the NRP1 coreceptor role.
• Signaling: In microglia, tuftsin signals through NRP1 coupled to TGF‑β receptor 1 to activate canonical TGF‑β/Smad3 signaling and modulate Akt, driving an M2 anti-inflammatory polarization and increased TGF‑β/IL‑10 output.

Overlap analysis: which peptides share Selank’s mechanisms?

• GABAergic modulation: Evidence supports overlap between Selank and Semax. Both influence inhibitory transmission—Selank modulates GABA-related gene expression and enhances inhibitory interneuron activity; Semax modulates GABA and glycine currents and GABA ligand–receptor interactions.
• Neurotrophin/BDNF–TrkB/CREB pathways: Semax robustly induces BDNF and TrkB and increases TrkB phosphorylation; ischemia studies implicate CREB activation. Selank reports BDNF upregulation and NCX3/Akt-linked neuroprotective signaling. Thus, Semax shares and more strongly exemplifies this pathway overlap with Selank; ACTH(6–9)PGP shares Semax’s transcriptomic neuroprotection signature.
• Immunomodulation and cytokine transcriptome shifts: Selank and Semax both reprogram inflammatory gene expression after brain injury; Selank also induces IFN‑α/IL‑12 and suppresses IL‑6 gene expression in immune cells. Tuftsin shares the immunomodulatory outcome but via a distinct, well-defined receptor/signaling axis—NRP1→TGF‑β/Smad3—rather than the GABAergic or neurotrophin mechanisms emphasized for Selank/Semax.
• Opioid/enkephalinase pathway: Inhibition of enkephalin-degrading enzymes is demonstrated for Selank; this specific mechanism is not evidenced for Semax or tuftsin in the collected sources, so this appears unique to Selank among the compared peptides here.

Conclusion

• Peptides with overlapping mechanisms to Selank: Semax (and related ACTH fragments) overlap most in (a) GABAergic modulation and (b) neurotrophin/BDNF–TrkB–linked neuroprotective signaling; they also share transcriptome-level anti-inflammatory and pro-neurotransmission effects after ischemia.
• Tuftsin overlaps with Selank in immunomodulatory outcomes but uses a distinct NRP1→TGF‑β/Smad axis; direct NRP1-based signaling has not been demonstrated for Selank in the gathered evidence.
• A unique Selank feature in this set is enkephalinase inhibition leading to elevated endogenous enkephalins.

Combination and Synergy#

Summary of findings. Across preclinical literature, Selank is most often studied alongside another regulatory peptide, Semax, in parallel arms rather than the same treatment arm. These studies consistently show that each peptide improves outcomes in wound repair, immunomodulation under stress, and hepatotoxic injury models, which supports complementary therapeutic domains. However, no retrieved study included a true co-administration arm (Selank+Semax together) with formal synergy testing; thus, evidence supports complementarity across separate arms but does not establish pharmacologic synergy from combined dosing.

Wound healing models. In a standardized rat thermal burn model (n=36), Semax or Selank was given intraperitoneally at 100 μg/kg/day beginning day 1 after injury. Animals were allocated into intact, burn control, and two peptide-treatment groups (Semax arm; Selank arm). Outcomes favored both peptides compared with untreated burns: earlier reparative signs (initiation of granulation and epithelization, earlier scab rejection), restricted destructive processes in epidermis/dermis, and partial closure of the defect, plus normalization of leukocyte indices (e.g., >50% reduction of band neutrophils, normalization of segmented neutrophils). The design used separate arms and did not evaluate co-administration; therefore, it demonstrates complementary efficacy profiles rather than synergy of a combination.

Immunomodulation under stress. In a “social” stress model using sensory contact/inter-confrontation, Semax and Selank were assessed in separate groups. Endpoints included delayed-type hypersensitivity, agglutination titers, neutrophil phagocytic activity, and leukocyte formula. Each peptide restored cellular and humoral immune responses perturbed by stress, indicating immunocorrective properties. No arm administered Selank+Semax together, so synergy was not tested.

Hepatoprotection models. In rodent drug-induced hepatitis models simulating anti-tuberculosis regimens (isoniazid, rifampicin, ethanol), Semax and Selank were compared to standard hepatoprotectors. Both peptides showed greater therapeutic activity than comparators, with parallel restoration of blood biochemistry and liver histomorphology and evidence of enhanced regenerative processes. The reports do not clarify any co-administration of Selank+Semax in the same arm; conclusions support that each peptide is effective, consistent with complementary actions rather than demonstrated synergy.

Mechanistic complementarity. Comparative work on glyprolines, Semax, and Selank shows overlapping but distinct effects on hemostasis and fibrinolysis (e.g., fibrin depolymerization, t-PA activity, antiplatelet actions), which could plausibly complement wound repair cascades, although this was not tested in a combined Selank+Semax arm. Broader reviews of Semax and Selank emphasize their multi-target neuroimmune actions and clinical utility in different indications, implying potential complementarity but providing no direct combination data.

Conclusion. Evidence to date indicates complementary effects when Selank is evaluated alongside Semax across preclinical models of wound healing, stress-related immune dysregulation, and hepatotoxic injury. However, formal synergy from co-administration has not been demonstrated in the retrieved literature because studies used separate treatment arms and did not include Selank+Semax combination arms or synergy analyses. Future experiments should randomize to monotherapy arms and a combination arm with predefined additive/synergistic interaction analyses to determine whether co-administration yields supra-additive benefits.

Evidence Gaps#

Direct head-to-head comparison studies between Selank and related peptides are limited. Most comparisons are based on separate studies with different methodologies, making direct efficacy comparisons difficult.

Related Reading#

• Selank overview and research guide
• Selank research evidence
• Selank dosing protocols